TOG Review (RCOG Journal)

MRCOG Part 2

Antenatal Care

Applications for cell-free fetal DNA testing beyond common aneuploidy

Key Statistics

  • 90% / 10% — Maternal / fetal-placental cfDNA
  • ~50% — Collective PPV, any SCA
  • 9% — Pooled PPV, rare autosomal trisomy

Don't-miss facts

  1. Confirm every high-chance expanded cffDNA result with amniocentesis (not CVS) — overcomes confined placental mosaicism

  2. Any SCA: collective PPV ~50%; monosomy X lowest (29.5–32%); FPR up to 90% in low-risk cohorts — consider undiagnosed maternal SCA

  3. RAT pooled PPV 9%; >97% are CPM; commonest is trisomy 7; no international body recommends RAT screening

  4. CNV platforms resolve only >7 Mb; sensitivity 14–20% for CNVs <5 Mb. No UK body endorses CNV screening; ACMG offers 22q11.2 to all

  5. Maternal carriage of a CNV is a contraindication to cffDNA screening for that CNV

  6. Trisomy 6, 7, 11, 14, 15 or 20 confirmed on invasive testing → methylation studies for UPD + clinical genetics referral

  7. Multiple aneuploidies on NIPT → think maternal malignancy (70% confirmed in Dutch series, mostly lymphoma); MDT pathway, IDENTIFY study ongoing

  8. UK Ground E TOP after 24 weeks is hard to justify for SCA given the wide phenotypic spectrum; beware indirect sex selection

PPV at a glance

22q11.2 (SMART): 52.6% Any SCA: ~50% Segmental CNV: 37.5–44.1% RAT: 9%

Abbreviation Key

  • cfDNA — cell-free DNA
  • UPD — uniparental disomy
  • cffDNA — cell-free fetal DNA
  • PPV — positive predictive value
  • NIPT — non-invasive prenatal screening/testing
  • FPR — false positive rate
  • NIPD — non-invasive prenatal diagnosis
  • POC — products of conception
  • SCA — sex chromosome aneuploidy
  • SNP — single nucleotide polymorphism
  • CNV — copy number variant
  • ACMG — American College of Medical Genetics and Genomics
  • RAT — rare autosomal trisomy
  • TOP — termination of pregnancy
  • CPM — confined placental mosaicism
  • Mb — megabase

Source: Ferguson G, Kilby MD, Mone F. Applications for cell-free fetal DNA testing beyond common aneuploidy. The Obstetrician & Gynaecologist 2025;27:197–206. doi:10.1111/tog.12988

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free